Enhanced Variant Enzymes for Advanced Biotechnological Applications

Introduction

Enzymes are the workhorses of biochemical processes across industries, from pharmaceuticals to biofuel production. However, natural enzymes often have limitations in stability, activity, or specificity that can hinder their effectiveness in various applications. Our patented variant enzymes offer an advanced solution to these challenges by providing engineered enzymes with optimized properties tailored to specific industrial or therapeutic needs. With enhanced stability, activity, and substrate specificity, these variant enzymes represent a versatile tool for improving efficiency and performance in a range of fields, from drug development to industrial bioprocessing.

Limits of Natural Enzymes in Biotechnology and Industry

While natural enzymes play a vital role in processes such as drug synthesis, biofuel production, and food processing, their performance can be limited by factors such as temperature sensitivity, pH instability, or poor specificity for the desired substrate. In industrial processes, this can lead to inefficiencies, increased costs, or the need for additional steps to ensure the desired outcome. Similarly, in the pharmaceutical and therapeutic arenas, naturally occurring enzymes may not be suitable for use in drug formulations or therapeutic applications due to these same limitations.

As industries increasingly rely on enzymes for sustainable processes and precision medicine, there is a growing demand for enzymes that perform optimally under specific conditions. Engineered or variant enzymes, designed to meet these demands, can offer enhanced stability, activity, and selectivity, leading to more efficient processes and better outcomes.

Engineered Enzymes for Tailored Biochemical Solutions

Our variant enzymes are designed to overcome the limitations of natural enzymes by optimizing key parameters such as temperature tolerance, pH stability, and catalytic efficiency. These engineered enzymes are ideal for applications where conventional enzymes fall short, providing a reliable, efficient solution for processes that require highly specific enzymatic activity. Whether it’s for enhancing the production of biofuels, improving the efficiency of pharmaceutical manufacturing, or enabling more precise biochemical reactions, our variant enzymes offer flexibility and performance that can be customized to meet a variety of industrial and therapeutic needs.

For industries looking to improve their bioprocessing capabilities, variant enzymes offer a way to reduce costs, increase productivity, and enhance the quality of the final product. In the pharmaceutical space, these enzymes can be used to develop more effective drug therapies or to improve the delivery and action of enzyme-based treatments.

Key Benefits

  • Enhanced Stability and Activity: Variant enzymes are designed to perform under more challenging conditions, increasing efficiency.
  • Customizable for Specific Applications: Tailored to meet the unique needs of various industries, from pharmaceuticals to biofuels.
  • Improved Efficiency: Reduces the need for additional steps or conditions in industrial processes, saving time and costs.
  • Broad Applications: Suitable for use in multiple industries, including biotechnology, pharmaceuticals, and agriculture.

Enabling Advanced Enzyme Applications for Industry and Medicine

Licensing this variant enzyme technology provides biotech and pharmaceutical companies with a powerful tool for improving enzyme-based processes. With the ability to customize enzymes for specific conditions and applications, this technology enables more efficient, cost-effective solutions for bioprocessing, drug development, and industrial applications.

Disclosed are glycosyl hydrolase enzyme variants, particularly variants of certain oxidoreductases of glycosyl hydrolase family 61. Nucleic acids encoding the glycosyl hydrolyase variants, compositions including the glycosyl hydrolase variants, methods of producing the variants, and methods of using the variants are also described.

What is claimed is:

1. A variant glycoside hydrolase family 61 (GH61) polypeptide, wherein said variant has cellulase enhancing activity, has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:3 and the amino acid substitution I114L, and has at least one improved property relative to a parent GH61 polypeptide, wherein said improved property is selected from the group consisting of (a) expression based on protein level and RNA level or activity of the variant GH61 polypeptide, (b) thermostability and/or melting temperature (Tm), (c) performance in a Whole Hydrolysate Dilute Acid Pretreated Corn Stover (whPCS) hydrolysis assay.
2. The variant of claim 1, wherein said variant is a combinatorial variant.
3. The variant of claim 1, wherein said parent GH61 polypeptide is a fungal glycosyl hydrolase 61a (GH61A).
4. The variant of claim 3, wherein said fungal GH61A is from Hypocrea jecorina, Hypocrea rufa, Hypocrea orientalis, Hypocrea atroviridis, Hypocrea virens, Emericella nidulans, Aspergillus terreus, Aspergillus oryzae, Aspergillus niger, Aspergillus kawachii, Aspergillus flavus, Aspergillus clavatus, Gaeumannomyces graminis, Trichoderma saturnisporum, Neurospora tetrasperma, Neurospora crassa, Neosartorya fumigata, Neosartorya fumigate, Neosartorya fischeri, Thielavia terrestris, Talaromyces sp., Sporotricum sp, and Thielavia heterothallica.

Share

Title

Variant enzymes

Inventor(s)

Nicholai DOUGLAS, Maria FOUKARAKI, Ronaldus Wilhelmus HOMMES, Thijs Kaper, Bradley R. Kelemen, Slavko Kralj, Suzanne E. Lantz, Jonathan K. LassilaIgor Nikolaev, Daniel Esteban Torres-Pazmino, Wilhelmus VAN DER KLEY, Johannes Franciscus Thomas VAN LIESHOUT, Sander Van Stigt Thans

Assignee(s)

Danisco US Inc

Patent #

10479983

Patent Date

November 19, 2019

Inquire about this intellectual property

Learn more about "Enhanced Variant Enzymes for Advanced Biotechnological Applications"